Related Experiment Video
Updated: Jul 4, 2026
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
The novel arthritis-drug substance MCS-18 attenuates the antibody production in vivo
F Kerek1, G Szegli, Lidia Cremer
1Cantacuzino Institute for Microbiology and Immunology, Bucharest, Romania. kerek@donatur.de
Unlabelled:
Influence of the novel arthritis drug-substance MCS-18 on the antibody (Ab) production against tetanus toxoid (TT) and diphtheria toxoid (DT) antigens was tested in vivo. Possible involvement of MCS-18 in Toll-like receptor (TLR) signalling pathway was further considered.
Materials And Methods:
Immunization of male CD1 mice was done with subcutaneous injection of TT emulsified in Freund's Complete (FCA) or Incomplete Adjuvant (FIA) and mixed diversly with MCS-18 and different test substances. To investigate the influence of TLR activation Pam3Cys and lipopolysaccharide (LPS) emulsified in FIA were tested in combinations with MCS-18. Antibody production was analysed in vivo by tetanus- or diphtheria-toxin neutralization test.
Results:
Immunogenicity of TT was significantly enhanced if administered together with FCA or TLR agonists Pam3Cys or LPS emulsified in FIA. It was shown that MCS-18 attenuated strongly the production of anti-TT Ab if administered together with the Ab elicitor FCA or TLR agonists in various combinations. MCS-18 was also active via oral administration.
Discussion:
These findings suggest that MCS-18 could be a potent, non-toxic antagonist or a down-regulator of TLR signalling pathway. Investigations on further models are needed to establish ifMCS-18 may influence particularly the production of RA-specific auto-antibodies, too.
Insights
The novel arthritis drug MCS-18 significantly reduced antibody production against tetanus toxoid when combined with adjuvants or Toll-like receptor agonists. This suggests MCS-18 may act as a Toll-like receptor signaling pathway antagonist.
Area of Science:
- Immunology
- Pharmacology
Background:
- The novel arthritis drug MCS-18's effect on antibody production was investigated.
- Its potential role in the Toll-like receptor (TLR) signaling pathway was explored.
Purpose of the Study:
- To determine the in vivo influence of MCS-18 on antibody (Ab) production against tetanus toxoid (TT) and diphtheria toxoid (DT).
- To assess the potential involvement of MCS-18 in the TLR signaling pathway.
Main Methods:
- Male CD1 mice were immunized with TT emulsified in Freund's Complete Adjuvant (FCA) or Incomplete Adjuvant (FIA).
- Combinations of MCS-18 with TT, FCA, or TLR agonists (Pam3Cys, LPS) were tested.
- Antibody production was analyzed via tetanus- or diphtheria-toxin neutralization tests.
Main Results:
- Immunogenicity of TT was enhanced by FCA or TLR agonists.
- MCS-18 significantly attenuated anti-TT antibody production when co-administered with FCA or TLR agonists.
- MCS-18 demonstrated efficacy through oral administration.
Conclusions:
- MCS-18 shows potential as a non-toxic antagonist or down-regulator of the TLR signaling pathway.
- Further research is needed to confirm its influence on rheumatoid arthritis (RA)-specific auto-antibodies.
